Shukra Pharmaceuticals

20.17
-0.41
(-1.99%)
Market Cap
883.25 Cr
EPS
16.93
PE Ratio
108.32
Dividend Yield
0.12 %
Industry
Healthcare
52 Week High
27.15
52 Week Low
5.75
PB Ratio
16.60
Debt to Equity
0.10
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,707.25
#1 4,09,626.46
36.01
#1 49,887.20
12.06
#1 9,648
13.77
59.55
5,498.10
1,45,957.28
74.00
8,184.00
0.89
1,600
#1 64.53
50.90
1,414.80
1,14,261.36
24.20
26,520.70
14.17
4,155
47.38
55.43
3,244.40
1,09,805.24
59.07
10,785.70
11.59
1,656
13.54
59.71
2,419.90
99,839.88
49.07
10,615.60
19.57
1,942
-16.38
56.35
1,105.00
92,207.32
#1 17.88
28,905.40
12.36
5,578
1.69
45.59
1,978.75
90,338.04
33.34
20,141.50
#1 19.94
1,936
38.82
56.82
865.00
87,039.24
20.00
19,831.50
13.82
3,831
29.92
49.00
1,110.15
64,477.69
19.37
29,559.20
17.55
3,169
-10.04
55.70
29,522.75
62,733.78
47.68
6,097.20
10.80
1,201
16.01
48.49
Growth Rate
Revenue Growth
29.00 %
Net Income Growth
320.45 %
Cash Flow Change
-264.04 %
ROE
84.62 %
ROCE
117.66 %
EBITDA Margin (Avg.)
162.67 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
Revenue
4
5
5
6
6
12
12
21
60
77
34
Expenses
3
4
4
4
4
10
10
18
54
55
20
EBITDA
1
1
2
2
2
2
2
3
7
22
14
Operating Profit %
-10 %
24 %
29 %
30 %
29 %
13 %
13 %
14 %
9 %
26 %
29 %
Depreciation
1
0
1
1
1
2
2
2
2
2
3
Interest
0
0
0
0
0
0
0
0
0
0
1
Profit Before Tax
0
0
1
1
1
0
0
1
4
20
11
Tax
0
0
1
0
0
0
-0
0
0
1
3
Net Profit
0
0
1
1
1
0
0
1
4
19
8
EPS in ₹
0.84
0.76
3.21
3.36
2.95
0.23
1.20
4.79
26.21
16.93
4.60

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
18
17
19
24
28
34
36
35
75
78
Fixed Assets
10
10
10
14
16
17
18
18
20
20
Current Assets
7
6
7
8
11
15
16
16
53
56
Capital Work in Progress
2
2
2
2
2
2
2
2
2
2
Investments
0
0
0
0
0
0
0
0
0
0
Other Assets
7
6
7
8
11
15
16
16
53
56
Total Liabilities
18
17
19
24
28
34
36
35
75
78
Current Liabilities
1
1
2
3
4
7
7
12
43
14
Non Current Liabilities
4
3
3
6
9
11
13
6
7
6
Total Equity
14
14
15
15
15
15
16
16
25
58
Reserve & Surplus
12
13
13
13
14
14
14
15
21
47
Share Capital
2
2
2
2
2
2
2
2
4
11

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
0
1
-1
-1
0
-0
0
-0
4
6
Investing Activities
1
-0
-1
-5
-3
-3
-2
-2
-4
-1
Operating Activities
-2
3
-0
1
0
1
1
8
3
-5
Financing Activities
1
-1
0
4
2
2
2
-7
5
12

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Aug 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
49.17 %
49.17 %
49.17 %
49.17 %
49.17 %
49.17 %
49.17 %
49.17 %
50.90 %
50.90 %
50.90 %
50.90 %
50.96 %
50.96 %
50.96 %
50.96 %
50.96 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.80 %
0.80 %
0.80 %
0.80 %
0.80 %
0.80 %
0.80 %
0.80 %
0.11 %
0.11 %
0.11 %
0.11 %
0.11 %
0.11 %
0.11 %
0.11 %
0.11 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
33.02 %
33.02 %
32.90 %
32.86 %
32.83 %
32.81 %
33.00 %
33.06 %
29.14 %
29.10 %
29.11 %
29.14 %
28.94 %
9.79 %
9.19 %
9.25 %
9.41 %
Others
17.01 %
17.01 %
17.14 %
17.18 %
17.21 %
17.22 %
17.04 %
16.98 %
19.85 %
19.88 %
19.88 %
19.85 %
19.99 %
39.14 %
39.73 %
39.68 %
39.51 %
No of Share Holders
9,345
9,345
9,305
9,268
9,239
9,193
9,237
9,234
9,544
9,582
9,600
9,747
10,963
12,974
14,989
16,321
17,844

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.5 0.5 0.5 0.00 0.00 0.5 0.5 1 0.00
Dividend Yield (%) 0.00 156.25 263.16 208.33 0.00 0.00 42.74 6.13 4.58 0.00

Corporate Action

Announcements

Intimation Of Change In Secretarial Auditor Of The Company5 days ago
Outcome Of Independent Directors Meeting Dated March 26 2025.8 days ago
Closure of Trading Window8 days ago
Corporate Action-Updates on intimation of Sub division / Stock SplitMar 20, 2025
Corporate Action-updates on Outcome of Sub division / Stock SplitMar 18, 2025
Intimation Of New ISIN.Mar 17, 2025
Intimation Of Record Date For Sub-Division Of Face Value Of Rs. 10/- Each To Face Value Of Re. 1/- EachMar 07, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 15, 2025
Integrated Filing (Financial)Feb 14, 2025
Submission Of Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended On 31St December 2024Feb 14, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. On 14Th February 2025 And Submission Of Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended On 31St DecFeb 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 05, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 04, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 And 33 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Feb 03, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. On January 29 2025 Pursuant To Regulation 30 Of SEBI (Listing And Obligations And Disclosure Requirements) Regulations 2015Jan 29, 2025
Board Meeting Intimation for Prior Intimation Of Board Of Directors Meeting- Regulation 29 Of SEBI (Listing And Obligation And Disclosure Requirement) Regulations 2015Jan 24, 2025
Board Meeting Outcome for Outcome Board Meeting Held On Thursday January 9 2025Jan 09, 2025
Closure of Trading WindowDec 30, 2024
Announcement Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulation 2015 ('SEBI LODR) For Intimation For Receipt Of In- Principal Approval From Stock Exchange Under Regulation 28(1) Of SEBI LODRNov 29, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 16, 2024
Un-Audited Financial Results Of The Company For The Second Quarter And Half Year Ended On 30Th September, 2024.Nov 14, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. On 14Th November, 2024 And Submission Of Un-Audited Financial Results Of The Company For The Second Quarter And Half Year Ended On 30Th September, 2024.Nov 14, 2024
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 And 33 Of SEBI (LODR) Regulations, 2015Nov 07, 2024
Appointment Of Sheetal Shah As Additional Promoter Director And Ritu Kapoor As Additional Independentdirector W.E.F. October 25, 2024Oct 25, 2024
Board Meeting Outcome for APPOINTMENT OF SHEETAL SHAH AS DIRECTOR AND RITU KAPOOR AS INDEPENDENT DIRECTOROct 25, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMOct 14, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportOct 03, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2024
Closure of Trading WindowSep 30, 2024
Corporate Action-Outcome of Right issueSep 28, 2024
Board Meeting Outcome for Consider And Approve Right Issue And Draft Offer LetterSep 28, 2024
Corporate Action-Outcome of Right issueSep 28, 2024
Board Meeting Outcome for Rights Issues Of Equity SharesSep 28, 2024
Board Meeting Intimation for Shukra Pharmaceuticals Ltd Has Informed BSE That The Meeting Of The Board Of Directors Of The Company Is Scheduled On Saturday, September 28, 2024.Sep 23, 2024
Corporate Action Book Closure For AGMSep 17, 2024
Notice For Convening The AGM Of Shukra Pharmaceuticals LimitedSep 15, 2024
Reg. 34 (1) Annual Report.Sep 14, 2024
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 27, 2024
Shareholder Meeting / Postal Ballot-Outcome of EGMAug 23, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2024
Financial Results For The Quarter Ended June 30, 2024Aug 12, 2024
Board Meeting Outcome for Approval Of Unaudited Financial Results For The Quarter Ended June 30, 2024Aug 12, 2024
Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended June 30, 2024Aug 03, 2024
Notice Of EGM Dated 23Rd August, 2024Jul 30, 2024
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationJul 23, 2024
Board Meeting Outcome for Increase In Authorised Share CapitalJul 23, 2024
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)Jul 10, 2024
Announcement under Regulation 30 (LODR)-Change in DirectorateJul 10, 2024

Technical Indicators

RSI(14)
Neutral
35.56
ATR(14)
Less Volatile
0.59
STOCH(9,6)
Oversold
0.00
STOCH RSI(14)
Oversold
0.00
MACD(12,26)
Bearish
-0.50
ADX(14)
Weak Trend
22.35
UO(9)
Bullish
14.21
ROC(12)
Downtrend And Accelerating
-17.91
WillR(14)
Oversold
-100.00